Founder And CEO
Co-Founding Partner and COO
Chief Financial Officer
Chief People Officer
Partner, Insights and Analytics
Senior Partner, Insights and Analytics
Partner, Insights and Analytics
Partner, Insights and Analytics
Principal, Launch Excellence
Partner, Launch Excellence Practice Lead
Principal, Global Value and Access
Principal, Global Value and Access
Senior Partner, Global Value and Access
Principal, Global Value and Access
Principal, Market Access
Principal, Market Access
Partner, Medical Affairs
Partner, Medical Affairs
Partner, Medical Affairs
Partner
Senior Partner, Patient Services Lead
Vice President, Market Access and HEOR
Principal
Principal
Vice President, Commercialization
Head of Business Development
Director, Business Development & Client Success
Esther founded Decisive Consulting in 2020 following 23 years’ experience in the pharmaceutical and biotechnology industry at national, regional, and international levels.
Over her career, Esther has built and led Market Access and HEOR organizations and has additionally led all commercial functions across international markets. She is best known for her ability to solve complex problems, from optimizing organizational ways of working to addressing specific external challenges and finding the hidden opportunity.
Recently recognized as “One to Watch” in the 2024 Times and LDC Top 50 Most Ambitious Business Leaders awards, Esther is passionate about diversity and inclusion and champions “rebel thinking” to uncover new possibilities.
Overview of the EU pharmaceutical legislation agreement and its implications for the industry, from market exclusivity to regulatory reform. Read here.
Explore how the National Cancer Plan for England is reshaping oncology access expectations, regulatory timelines, and HTA and JCA planning. Read here.
NICE updates its cost-effectiveness threshold. Discover the implications of this change for the UK HTA, patient access, and pricing strategy. Read here.
Discover seven strategic lessons to strengthen your Joint Clinical Assessment (JCA) dossier. Read here.
The UK’s VPAG is more than a cost-control tool; it can become a model for global medicines access. Read here.
Learn the key steps to JCA readiness. Anticipate PICO scenarios, align evidence with EU HTA, and accelerate market access success. Read here.
In July 2025, the Italian Medicines Agency (AIFA) revised its drug innovativeness criteria, ending “conditional” status and prioritizing rare and ultra-rare diseases. Read here.
Discover how Most Favored Nation (MFN) policy impacts U.S. drug pricing and market access in 2025, from CMS enforcement to launch planning. Get the whitepaper now.
President Trump’s July 31st letter creates a rising imperative that cannot be ignored. Learn more about the notable escalations and expansions.
"*" indicates required fields
Careers page, Principal profile
Careers page Manager profile
Careers page Analyst profile